Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 30;14(13):3206.
doi: 10.3390/cancers14133206.

Concurrent Androgen Deprivation Therapy for Prostate Cancer Improves Survival for Synchronous or Metachronous Non-Small Cell Lung Cancer: A SEER-Medicare Database Analysis

Bassel Nazha  1 , Chao Zhang  2 , Zhengjia Chen  3   4 , Camille Ragin  5 , Taofeek K Owonikoko  6
Affiliations

Concurrent Androgen Deprivation Therapy for Prostate Cancer Improves Survival for Synchronous or Metachronous Non-Small Cell Lung Cancer: A SEER-Medicare Database Analysis

Bassel Nazha et al. Cancers (Basel). .

Abstract

Introduction: The crosstalk between receptor kinase signaling, such as EGFR and androgen receptor signaling, suggests a potential interaction between androgen deprivation therapy (ADT) and lung cancer outcome. Methods: We employed the SEER−Medicare data of lung cancer patients diagnosed between 1988 and 2005 to test for an association between ADT for prostate cancer and lung cancer outcome. We employed the Kaplan−Meier method and Cox proportional hazard with log-rank test model to assess any significant impact of ADT on survival. Results: We included data from 367,750 lung cancer patients; 17.4%, 2.9%, 33.6% and 46.1% with stages I, II, III and IV, respectively; 84.5% were >65 years; 57.2% males; 84.2% Caucasians and 9.3% Blacks. There were 11,061 patients (3%) with an initial prostate cancer diagnosis followed by lung cancer (P-L group); 3017 (0.8%) with an initial diagnosis of lung cancer and subsequent prostate cancer diagnosis (L-P group); the remainder had only lung cancer (L group). Stage I lung cancer was most common in the L-P group compared to the L and P-L groups—54% vs. 17.13% vs. 17.92%, p < 0.0001 for L-P, L and P-L, respectively. The median OS for lung cancer diagnosis was 93 months versus 10 and 9 months, respectively, for the L-P, L and P-L subgroups. ADT was associated with improved survival on multivariate analysis, especially in Caucasian patients (HR of death: 0.86; 95% CI: 0.76−0.97; p = 0.012). Conclusion: ADT was associated with improved outcome for NSCLC, in line with the hypothesis of a role for the androgen receptor in lung cancer. Our findings support a systematic evaluation of the potential benefit of ADT as a therapy for lung cancer.

Keywords: SEER; androgen deprivation therapy; hormonal therapy; lung cancer; prostate cancer.

PubMed Disclaimer

Conflict of interest statement

B.N. reports a paid advisory board role for Exelixis and was a paid participant in a case discussion for IntrinsiQ Specialty Solutions—AmerisourceBergen. T.K.O. reports a paid advisory board role for BMS, AstraZeneca and Merck, and a paid consultancy (data monitoring board) for Roche/Genentech and EMD Serono. All other authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Kaplan–Meier plot for overall survival (OS) comparing the three subgroups, L, P-L and L-P.
Figure 2
Figure 2
Kaplan–Meier plot for overall survival (OS) in P-L subgroup comparing patients treated with and without ADT.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. American Cancer Society Key Statistics for Lung Cancer. 2019. [(accessed on 10 July 2020)]. Available online: https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html.
    1. Torre L.A., Siegel R.L., Ward E.M., Jemal A. International Variation in Lung Cancer Mortality Rates and Trends among Women. Cancer Epidemiol. Biomark. Prev. 2014;23:1025–1036. doi: 10.1158/1055-9965.EPI-13-1220. - DOI - PubMed
    1. Torre L.A., Siegel R.L., Jemal A. Lung Cancer and Personalized Medicine. Springer; Berlin/Heidelberg, Germany: 2016. Lung cancer statistics; pp. 1–19. - PubMed
    1. Jemal A., Miller K.D., Ma J., Siegel R.L., Fedewa S.A., Islami F., Devesa S.S., Thun M.J. Higher Lung Cancer Incidence in Young Women Than Young Men in the United States. N. Engl. J. Med. 2018;378:1999–2009. doi: 10.1056/NEJMoa1715907. - DOI - PMC - PubMed
    1. North C.M., Christiani D.C. Women and lung cancer: What is new? Semin. Thorac. Cardiovasc. Surg. 2013;25:87–94. doi: 10.1053/j.semtcvs.2013.05.002. - DOI - PMC - PubMed